Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates

被引:86
作者
Zhao, Hui [1 ]
Atkinson, John [1 ]
Gulesserian, Sara [1 ]
Zeng, Zhilan [1 ]
Nater, Jenny [1 ]
Ou, Jimmy [1 ]
Yang, Peng [1 ]
Morrison, Karen [1 ]
Coleman, Jeffrey [1 ]
Malik, Faisal [1 ]
Challita-Eid, Pia [1 ]
Karki, Sher [1 ]
Avina, Hector [1 ]
Hubert, Rene [1 ]
Capo, Linnette [1 ]
Snyder, Josh [1 ]
Moon, Sung-Ju [1 ]
Luethy, Roland [1 ]
Mendelsohn, Brian A. [1 ]
Stover, David R. [1 ]
Donate, Fernando [1 ]
机构
[1] Agensys Inc, Santa Monica, CA USA
关键词
RENAL-CELL CARCINOMA; NON-HODGKIN-LYMPHOMA; TRASTUZUMAB EMTANSINE; DOSE-ESCALATION; BREAST-CANCER; ADC; INHIBITION; CHALLENGES; DISCOVERY; RECEPTOR;
D O I
10.1158/0008-5472.CAN-17-3202
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AGS-16C3F is an antibody-drug conjugate (ADC) against ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) containing the mcMMAF linker-payload currently in development for treatment of metastatic renal cell carcinoma. AGS-16C3F and other ADCs have been reported to cause ocular toxicity in patients by unknown mechanisms. To investigate this toxicity, we developed an in vitro assay using human corneal epithelial cells (HCEC) and show that HCECs internalized AGS-16C3F and other ADCs by macropinocytosis, causing inhibition of cell proliferation. We observed the same mechanism for target-independent internalization of AGS-16C3F in fibroblasts andhuman umbilical vein endothelial cells (HUVEC). Macropinocytosis-mediated intake of macromolecules is facilitated by the presence of positive charges or hydrophobic residues on the surface of the macromolecule. Modification of AGS-16C3F, either by attachment of polyglutamate peptides, mutation of residue K16 to D on AGS-16C3F [AGS-16C3F(K16D)], or decreasing the overall hydrophobicity via attachment of polyethylene glycol moieties, significantly reduced cytotoxicity against HCECs and other primary cells. Rabbits treated with AGS-16C3F showed significant ocular toxicity, whereas those treated with AGS-16C3F(K16D) presented with less severe and delayed toxicities. Both molecules displayed similar antitumor activity in a mouse xenograft model. These findings establish a mechanism of action for target-independent toxicities of AGS-16C3F and ADCs in general, and provide methods to ameliorate these toxicities. Significance: These findings reveal a mechanism for nonreceptor-mediated toxicities of antibody drug conjugates and potential solutions to alleviate these toxicities. (C) 2018 AACR.
引用
收藏
页码:2115 / 2126
页数:12
相关论文
共 32 条
[21]   Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study [J].
Moore, Kathleen N. ;
Martin, Lainie P. ;
O'Malley, David M. ;
Matulonis, Ursula A. ;
Konner, Jason A. ;
Perez, Raymond P. ;
Bauer, Todd M. ;
Ruiz-Soto, Rodrigo ;
Birrer, Michael J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) :1112-+
[22]   A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [J].
Ribrag, Vincent ;
Dupuis, Jehan ;
Tilly, Herve ;
Morschhauser, Franck ;
Laine, Fabrice ;
Houot, Roch ;
Haioun, Corinne ;
Copie, Christiane ;
Varga, Andrea ;
Lambert, John ;
Hatteville, Laurence ;
Ziti-Ljajic, Samira ;
Caron, Anne ;
Payrard, Sandrine ;
Coiffier, Bertrand .
CLINICAL CANCER RESEARCH, 2014, 20 (01) :213-220
[23]   An FDA oncology analysis of antibody-drug conjugates [J].
Saber, Haleh ;
Leighton, John K. .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 71 (03) :444-452
[24]  
Secker GA, 2008, STEMBOOK MONOGRAPH I
[25]   First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors [J].
Shapiro, Geoffrey I. ;
Vaishampayan, Ulka N. ;
LoRusso, Patricia ;
Barton, Jeremy ;
Hua, Steven ;
Reich, Steven D. ;
Shazer, Ronald ;
Taylor, Carrie T. ;
Xuan, Dawei ;
Borghaei, Hossein .
INVESTIGATIONAL NEW DRUGS, 2017, 35 (03) :315-323
[26]   Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma [J].
Tannir, Nizar M. ;
Forero-Torres, Andres ;
Ramchandren, Radhakrishnan ;
Pal, Sumanta K. ;
Ansell, Stephen M. ;
Infante, Jeffrey R. ;
de Vos, Sven ;
Hamlin, Paul A. ;
Kim, Stella K. ;
Whiting, Nancy C. ;
Gartner, Elaina M. ;
Zhao, Baiteng ;
Thompson, John A. .
INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) :1246-1257
[27]  
THOMPSON JA, 2015, J CLIN ONCOL S, V33
[28]   Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer [J].
Tsuda, Mayuko ;
Takano, Yoji ;
Shigeyasu, Chika ;
Imoto, Shigeru ;
Yamada, Masakazu .
CORNEA, 2016, 35 (10) :1378-1380
[29]   PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs [J].
Turecek, Peter L. ;
Bossard, Mary J. ;
Schoetens, Freddy ;
Ivens, Inge A. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 105 (02) :460-475
[30]   An overview of current techniques for ocular toxicity testing [J].
Wilson, Samantha L. ;
Ahearne, Mark ;
Hopkinson, Andrew .
TOXICOLOGY, 2015, 327 :32-46